“The resignation comes as a surprise and we believe it is untimely given it is too close to FY2022 results release,” says DBS in a Feb 23 note.
DBS Group Research has maintained its “buy” call and $2.55 target price on IHH Healthcare, following the “surprised” resignation of CEO and managing director Kelvin Loh.
No further details were provided, other than Loh is leaving voluntarily.
